You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

Details for Patent: 9,951,043


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 9,951,043 protect, and when does it expire?

Patent 9,951,043 protects SUNLENCA and is included in two NDAs.

This patent has sixty-six patent family members in thirty-six countries.

Summary for Patent: 9,951,043
Title:Therapeutic compounds
Abstract:Compounds of formula (I) or salts thereof are disclosed. Also disclosed are pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I and therapeutic methods for treating a Retroviridae viral infection including an infection caused by the HIV virus.
Inventor(s):Brizgys Gediminas, Canales Eda, Chou Chien-hung, Graupe Michael, Halcomb Randall L., Hu Yunfeng Eric, Lazerwith Scott E., Link John O., Liu Qi, Lu Yafan, Saito Roland D., Schroeder Scott D., Somoza John R., Tse Winston C., Zhang Jennifer R.
Assignee:Gilead Sciences, Inc.
Application Number:US14771779
Patent Claim Types:
see list of patent claims
 

Drugs Protected by US Patent 9,951,043

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Gilead Sciences Inc SUNLENCA lenacapavir sodium SOLUTION;SUBCUTANEOUS 215973-001 Dec 22, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y IN COMBINATION WITH OTHER ANTIRETROVIRAL(S), FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY-TREATMENT EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION ⤷  Sign Up
Gilead Sciences Inc SUNLENCA lenacapavir sodium TABLET;ORAL 215974-001 Dec 22, 2022 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y IN COMBINATION WITH OTHER ANTIRETROVIRAL(S), FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY-TREATMENT EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 9,951,043

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 094990 ⤷  Sign Up
Argentina 118856 ⤷  Sign Up
Australia 2014223973 ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.